Expression levels of Akt in nimesulide-treated squamous carcinoma cell lines of the head and neck

Oncology Reports

Volumn 13, Issue 2, 2005, Pages 207-210

  Vormittag, Laurenz ^a   Lamm, Wolfgang ^a   Erovic, Boban M ^a   Czembirek, Cornelia ^a   Kornek, Gabriela ^a   Thurnher, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Akt; Head and neck cancer; Nimesulide; Selective cyclooxygenase 2 inhibitor

Indexed keywords

AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NIMESULIDE; ONCOPROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CELL CULTURE; DRUG ANTAGONISM; HEAD AND NECK TUMOR; HUMAN; METABOLISM; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 16244419407     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD and Shapiro S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355-358, 1991.
2. Piazza GA, Rahm AL, Krutzsch M, et al: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995.
3. Leng J, Han C, Demetris AJ, Michalopoulos GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38: 756-768, 2003. (Pubitemid 37052162)
4. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000. (Pubitemid 30212792)
5. Thurnher D, Bakroeva M, Schutz G, et al: Non-steroidal anti-inflammatory drugs induce apoptosis in head and neck cancer cell lines. Acta Otolaryngol 121: 957-962, 2001. (Pubitemid 34084435)
6. Buecher B, Broquet A, Bouancheau D, et al: Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. Dig Liver Dis 35: 557-565, 2003. (Pubitemid 41070412)
7. Tian G, Yu JP, Luo HS, Yu BP, Yue H, Li JY and Mei Q: Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells. World J Gastroenterol 8: 483-487, 2002. (Pubitemid 34692747)
8. Wun T, McKnight H and Tuscano JM: Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 28: 179-190, 2004. (Pubitemid 37487998)
9. Chang F, Lee JT, Navolanic PM, et al: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590-603, 2003. (Pubitemid 36395654)
10. Hutchinson J, Jin J, Cardiff RD, Woodgett JR and Muller WJ: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203-2212, 2001. (Pubitemid 32479640)
11. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
12. Fresno Vara JA, Casado E, de Castro J, el al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
13. Bergmann A: Survival signaling goes BAD. Dev Cell. 3: 607-608, 2002.
14. Chinnaiyan AM: The apoptosome: heart and soul of the cell death machine. Neoplasia 1: 5-15, 1999.
15. Kops GJ and Burgering BM: Forkhead transcription factors: new insights into protein kinase B (c-akt) signalling. J Mol Med 77: 656-665, 1999. (Pubitemid 29500958)
16. Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 159: 387-397, 2001. (Pubitemid 32751067)
17. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
18. Cheng JQ, Godwin AK, Bellacosa A, et al: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
19. Ruggeri BA, Huang L, Wood M, Cheng JQ and Testa JR: Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 21: 81-86, 1998. (Pubitemid 28122842)
20. Nakayama H, Ikebe T, Beppu M and Shirasuna K: High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044, 2001. (Pubitemid 33136198)
21. Brown J, O'Prey J and Harrison PR: Enhanced sensitivity of human oral tumours to the flavonol, morin, during cancer progression: involvement of the Akt and stress kinase pathways. Carcinogenesis 24: 171-177, 2003. (Pubitemid 36267083)
22. Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt implications for cancer therapy. Pharmacol Ther 93: 243-251, 2002. (Pubitemid 34615565)
23. Rosenquist M: 14-3-3 proteins in apoptosis. Braz J Med Biol Res 36: 403-408, 2003.
24. Hermeking H: The 14-3-3 cancer connection. Nat Rev Cancer 3: 931-943, 2003.
25. Villaret DB, Wang T, Dillon D, et al: Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 110: 374-381, 2000. (Pubitemid 30143678)
26. Lodygin D, Yazdi AS, Sander CA, Herzinger T and Hermeking H: Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22: 5519-5524, 2003. (Pubitemid 37072207)
27. Mishima K, Inoue K and Hayashi Y: Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38: 468-474, 2002. (Pubitemid 34756732)
28. Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689, 1995.
29. Simon C, Hicks MJ, Nemechek AJ, et al: PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 80: 1412-1419, 1999. (Pubitemid 29308611)
30. Yang LC, Yang SH, Tai KW, Chou MY and Yang JJ: MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and therapeutic opportunities. J Oral Pathol Med 33: 37-45, 2004.
31. Pelzmann et al: Nimesulide and Indomethacin induce apoptosis in head and neck cancer cells. J Oral Path Med (In press).
32. Cao Y and Prescott SM: Many actions of cyclooxygenase 2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002. (Pubitemid 34111968)
33. Eibl G, Reber HA, Wente MN and Hines OJ: The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26: 33-41, 2003. (Pubitemid 36020264)
34. Li JY, Wang XZ, Chen FL, Yu JP and Luo HS: Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9: 915-920, 2003.
35. Gesbert F, Sellers WR, Signoretti S, Loda M and Griffin JD: BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 275: 39223-39230, 2000. (Pubitemid 32058940)
36. Hermeking H, Lengauer C, Polyak K, et al: 14-3-3 is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997. (Pubitemid 127376388)